Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Elan (Alzheimers Immunotherapy Program)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Alzheimers Immunotherapy Program is researching, developing and commercializing selective products for the treatment of Alzheimer's Disease. This includes bapineuzumab, a potential first-in-class treatment that is being evaluated for slowing the progression of Alzheimer's Disease.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Discovery Tools (Healthcare)
Primary Office
  • Treasury Building, Lower Grand Canal Street
  • Dublin 2
  • Ireland

Elan (Alzheimers Immunotherapy Program) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Elan (Alzheimers Immunotherapy Program)‘s full profile, request access.

Request full access to PitchBook

Elan (Alzheimers Immunotherapy Program) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Elan (Alzheimers Immunotherapy Program)‘s full profile, request access.

Request full access to PitchBook